Novel pharmacological approaches for the treatment of acne vulgaris

Bibliography

• Thiboutot D, Gollnick H, Bettoli V, et al. Global alliance to improve outcomes in acne. J Am Acad Dermatol 2009;60(5 Suppl):S1-50
   PubMed Web of Science ®Google Scholar
• Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol 2009;1(3):188-92
   PubMedGoogle Scholar
• Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol 2009;18(10):821-32
   PubMed Web of Science ®Google Scholar
• Zhang L, Li WH, Anthonavage M, et al. Melanocortin-5 receptor and sebogenesis. Eur J Pharmacol 2011;660(1):202-6
   PubMed Web of Science ®Google Scholar
• Piérard-Franchimont C, Piérard GE, Saint-Léger D, et al. Comparison of the kinetics of sebum secretion in young women with and without acne. Dermatologica 1991;183(2):120-2
   PubMedGoogle Scholar
• Trifu V, Tiplica GS, Naumescu E, et al. Cortexolone 17alpha-propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double-blind comparative study vs. placebo and tretinoin 0.05% cream. Br J Dermatol 2011;165(1):177-83
   PubMed Web of Science ®Google Scholar
• Lai JJ, Chang P, Lai KP, et al. The role of androgen and androgen receptor in skin-related disorders. Arch Dermatol Res 2012;304(7):499-510
   PubMed Web of Science ®Google Scholar
• Fritsch M, Orfanos CE, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 2001;116(5):793-800
   PubMed Web of Science ®Google Scholar
• Imperato-McGinley J, Gautier T, Cai LQ, et al. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993;76(2):524-8
   PubMed Web of Science ®Google Scholar
• Kelce W. Topical nitric oxide: a first class local antiandrogen therapy. (White Paper). Novan Therapeutics. Available from: http://www.novantherapeutics.com/files/8613/7398/9326/Topical_nitric_oxide_local_androgen_therapy.pdf [Last accessed 27 January 2014]
   Google Scholar
• Chen W, Zouboulis CC, Orfanos CE. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgendependent skin disorders. Dermatology 1996;193(3):177-84
   PubMed Web of Science ®Google Scholar
• Samson M, Labrie F, Zouboulis CC, Luu-The V. Biosynthesis of dihydrotestosterone by a pathway that does not require testosterone as an intermediate in the SZ95 sebaceous gland cell line. J Invest Dermatol 2010;130(2):602-4
   PubMed Web of Science ®Google Scholar
• Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol 2002;119(5):992-1007
   PubMed Web of Science ®Google Scholar
• Slominski A, Zbytek B, Nikolakis G, et al. Steroidogenesis in the skin: implications for local immune functions. J Steroid Biochem Mol Biol 2013;137:107-23
   PubMed Web of Science ®Google Scholar
• Sansone G, Davidson W, Cummings B, et al. Sebaceous gland lipogenesis induced by testosterone: early metabolic events. J Invest Dermatol 1971;57(3):144-8
   PubMed Web of Science ®Google Scholar
• Boudou P, Chivot M, Vexiau P, et al. Evidence for decreased androgen 5 alpha-reduction in skin and liver of men with severe acne after 13-cis-retinoic acid treatment. J Clin Endocrinol Metab 1994;78(5):1064-9
   PubMed Web of Science ®Google Scholar
• Lai JJ, Lai KP, Chuang KH, et al. Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J Clin Invest 2009;119(12):3739-51
   PubMed Web of Science ®Google Scholar
• George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008;27(3):188-96
   PubMed Web of Science ®Google Scholar
• Celasco G, Moro L, Bozzella R, et al. Biological profile of cortexolone 17alpha-propionate (CB-03-01), a new topical and peripherally selective androgen antagonist. Arzneimittelforschung 2004;54(12):881-6
   PubMed Web of Science ®Google Scholar
• An evaluation of the adrenal suppression potential and pharmacokinetic properties of CB-03-01 cream in subjects with acne vulgaris: Identifier NCT01831960. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris: Identifier NCT01631474. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Miyamoto H, Yang Z, Chen YT, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007;99(7):558-68
   PubMed Web of Science ®Google Scholar
• Lin TH, Izumi K, Lee SO, et al. Anti-androgen receptor ASC-J9 versus antiandrogens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis 2013;4:e764
   PubMed Web of Science ®Google Scholar
• Yang Z, Chang YJ, Yu IC, et al. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat Med 2007;13(3):348-53
   PubMed Web of Science ®Google Scholar
• A Phase 2 Study of ASC-J9 Cream in Acne Vulgaris. Identifier NCT00525499. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Topical ASC-J9 Cream for Acne: Identifier NCT01289574. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• AndroScience Corp. AndroScience Corporation Announces Phase 2a Study Results on ASC-J9. for the Treatment of Acne. [press release] March 6, 2009. 2009. Available from: http://www.androscience.com/artman/publish/news/pressrelease030609_printer.shtml [Accessed 27 January 2014]
   Google Scholar
• Sokanovic SJ, Baburski AZ, Janjic MM, et al. The opposing roles of nitric oxide and cGMP in the age-associated decline in rat testicular steroidogenesis. Endocrinology 2013;154(10):3914-24
   PubMed Web of Science ®Google Scholar
• Del Punta K, Charreau EH, Pignataro OP, et al. Nitric oxide inhibits Leydig cell steroidogenesis. Endocrinology 1996;137(12):5337-43
   PubMed Web of Science ®Google Scholar
• Pomerantz D, Pitelka V. Nitric oxide is a mediator of the inhibitory effect of activated macrophages on production of androgen by the Leydig cell of the mouse. Endocrinology 1998;139(3):922-31
   PubMed Web of Science ®Google Scholar
• Morgan ET, Ullrich V, Daiber A, et al. Cytochromes P450 and flavin monooxygenases – targets and sources of nitric oxide. Drug Metab Dispos 2001;29(11):1366-76
   PubMed Web of Science ®Google Scholar
• Drewett JG, Adams-Hays RL, Ho BY, et al. Nitric oxide potently inhibits the rate-limiting enzymatic step in steroidogenesis. Mol Cell Endocrinol 2002;194(1-2):39-50
   PubMed Web of Science ®Google Scholar
• Roediger WE, Hems R, Wiggins D, et al. Inhibition of hepatocyte lipogenesis by nitric oxide donor: could nitric oxide regulate lipid synthesis? IUBMB Life 2004;56(1):35-40
   PubMed Web of Science ®Google Scholar
• Sun B, Slomberg DL, Chudasama SL, et al. Nitric oxide-releasing dendrimers as antibacterial agents. Biomacromolecules 2012;13(10):3343-54
   PubMed Web of Science ®Google Scholar
• Carpenter AW, Schoenfisch MH. Nitric oxide release: part II. Therapeutic applications. Chem Soc Rev 2012;41(10):3742-52
   PubMed Web of Science ®Google Scholar
• Study of NVN1000 Topical Gel and Topical Gel Vehicle in the Treatment of Moderate to Severe Acne Vulgaris: Identifier NCT01556698. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers: Identifier NCT01755247. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers: Identifier NCT01694810. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel. Identifier NCT01844739. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Novan Announces Promising Results of SB204 Clinical Study: Phase 2 Clinical Results Expected Early 2014. May 30. 2013. Web. 27 Jan 2014. Available from: http://www.prnewswire.com/news-releases/novan-announcespromising-results-of-sb204-clinical-study-209483611.html
   Google Scholar
• A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne: Identifier NCT01844752. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Rico J, Quiring J, Hollenbach S, et al. Efficacy and safety of SB204 gel in the treatment of acne vulgaris. Poster session presented at: 73th Annual Meeting of the Society of Investigative Dermatology; 7-10 May 2014, Albuquerque, New Mexico. Available from: http://www.novantherapeutics.com/files/8913/9954/9470/SB204_Efficacy_and_Safety_Treatment_for_Acne.pdf. [Accessed 26 May, 2014]
   Google Scholar
• Thody AJ, Shuster S. Control of sebaceous gland function in the rat by alphamelanocyte-stimulating hormone. J Endocrinol 1975;64(3):503-10
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Sivarajah A, Gilliland Z, et al. The melanocortin 5 receptor is expressed in human sebaceous glands and rat preputial cells. J Invest Dermatol 2000;115(4):614-19
   PubMed Web of Science ®Google Scholar
• García-Borrón JC, Olivares C. Melanocortin 1 receptor and skin pathophisiology: beyond color, much more than meets the eye. Exp Dermatol 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Böhm M, Schiller M, Ständer S, et al. Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol 2002;118(3):533-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Anthonavage M, Huang Q, et al. Proopiomelanocortin peptides and sebogenesis. Ann NY Acad Sci 2003;994:154-61
   PubMed Web of Science ®Google Scholar
• Eisinger M, Li WH, Anthonavage M, et al. A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum specific lipids. J Dermatol Sci 2011;63(1):23-32
   PubMed Web of Science ®Google Scholar
• Hatta N, Dixon C, Ray AJ, et al. Expression, candidate gene, and population studies of the melanocortin 5 receptor. J Invest Dermatol 2001;116(4):564-70
   PubMed Web of Science ®Google Scholar
• Ganceviciene R, Böhm M, Fimmel S, et al. The role of neuropeptides in the multifactorial pathogenesis of acne vulgaris. Dermatoendocrinol 2009;1(3):170-6
   PubMedGoogle Scholar
• Chen WB, Kelly MA, Opitz-Araya X, et al. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 1997;91(6):789-98
   PubMed Web of Science ®Google Scholar
• Yaswen L, Diehl N, Brennan MB, Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin de.ciency responds to peripheral melanocortin. Nat Med 1999;5:1066-70
   PubMed Web of Science ®Google Scholar
• A Study of JNJ 10229570-AAA to Evaluate Safety and Tolerability in Japanese Participants With Acne Vulgaris: Identifier NCT01492647. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• A Study of a New Drug Treatment for Acne: Identifier NCT01326780. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Ben-Amitai D, Laron Z. Effect of insulin-like growth factor-1 deficiency or administration on the occurrence of acne. J Eur Acad Dermatol Venereol 2011;25(8):950-4
   PubMed Web of Science ®Google Scholar
• Smith TM, Cong Z, Gilliland KL, et al. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response elementbinding protein-1. J Invest Dermatol 2006;126(6):1226-32
   PubMed Web of Science ®Google Scholar
• Smith TM, Gilliland K, Clawson GA, et al. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008;128(5):1286-93
   PubMed Web of Science ®Google Scholar
• Ristow HJ, Messmer TO. Basic fibroblast growth factor and insulin-like growth factor I are strong mitogens for cultured mouse keratinocytes. J Cell Physiol 1988;137(2):277-84
   PubMed Web of Science ®Google Scholar
• Krane JF, Murphy DP, Carter DM, et al. Synergistic effects of epidermal growth factor (EGF) and insulin-like growth factor I/somatomedin C (IGF-I) on keratinocyte proliferation may be mediated by IGF-I transmodulation of the EGF receptor. J Invest Dermatol 1991;96(4):419-24
   PubMed Web of Science ®Google Scholar
• Barreca A, De Luca M, Del Monte P, et al. In vitro paracrine regulation of human keratinocyte growth by fibroblast-derived insulin-like growth factors. J Cell Physiol 1992;151(2):262-8
   PubMed Web of Science ®Google Scholar
• Gilhar A, Ish-Shalom S, Pillar T, et al. Effect of antiinsulin-like growth factor 1 on epidermal proliferation of human skin transplanted onto nude mice treated with growth hormone. Endocrinology 1994;134(1):229-32
   PubMed Web of Science ®Google Scholar
• Valentinis B, Baserga R. IGF-I receptor signalling in transformation and differentiation. Mol Pathol 2001;54(3):133-7
   PubMedGoogle Scholar
• Sadagurski M, Yakar S, Weingarten G, et al. Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol 2006;26(7):2675-87
   PubMed Web of Science ®Google Scholar
• Melnik BC, Schmitz G. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp Dermatol 2009;18(10):833-41
   PubMed Web of Science ®Google Scholar
• Im M, Kim SY, Sohn KC, et al. Epigallocatechin-3-gallate suppresses IGF-I induced lipogenesis and cytokine expression in SZ95 sebocytes. J Invest Dermatol 2012;13(12):2700-8
   Google Scholar
• Alestas T, Ganceviciene R, Fimmel S, et al. Enzymes involved in the biosynthesis of leukotriene B4 and prostaglandin E2 are active in sebaceous glands. J Mol Med 2006;84(1):75-87
   PubMed Web of Science ®Google Scholar
• Aizawa H, Niimura M. Elevated serum insulin-like growth factor-1 (IGF-1) levels in women with postadolescent acne. J Dermatol 1995;22(4):249-52
   PubMedGoogle Scholar
• Cappel M, Mauger D, Thiboutot D. Correlation between serum levels of insulin-like growth factor 1, dehydroepiandrosterone sulfate, and dihydrotestosterone and acne lesion counts in adult women. Arch Dermatol 2005;141(3):333-8
   PubMed Web of Science ®Google Scholar
• Vora S, Ovhal A, Jerajani H, et al. Correlation of facial sebum to serum insulin-like growth factor-1 in patients with acne. Br J Dermatol 2008;159(4):990-1
   PubMed Web of Science ®Google Scholar
• Isard O, Knol AC, Ariès MF, et al. Propionibacterium acnes activates the IGF-1/IGF-1R system in the epidermis and induces keratinocyte proliferation. J Invest Dermatol 2011;131(1):59-66
   PubMed Web of Science ®Google Scholar
• Liao S. The medicinal action of androgens and green tea epigallocatechin gallate. Hong Kong Med J 2001;7(4):369-74
   PubMedGoogle Scholar
• Mahmood T, Akhtar N, Khan BA, et al. Outcomes of 3% green tea emulsion on skin sebum production in male volunteers. Bosn J Basic Med Sci 2010;10(3):260-4
   PubMed Web of Science ®Google Scholar
• Elsaie ML, Abdelhamid MF, Elsaaiee LT, et al. The efficacy of topical 2% green tea lotion in mild-to-moderate acne vulgaris. J Drugs Dermatol 2009;8(4):358-64
   PubMed Web of Science ®Google Scholar
• Yoon JY, Kwon HH, Min SU, et al. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. J Invest Dermatol 2013;133(2):429-40
   PubMed Web of Science ®Google Scholar
• EGCG Improves Acne by Modulating Molecular Targets: Identifier NCT01687556. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Zouboulis CC, Nestoris S, Adler YD, et al. A new concept for acne therapy: a pilot study with zileuton, and oral 5-lipoxygenase inhibitor. Arch Dermatol 2003;139(5):668-70
   PubMed Web of Science ®Google Scholar
• Elmongy NN, Shaker O. Expression of peroxisome proliferator activator receptor β/δ (PPARβ/δ) in acne vulgaris. Eur J Dermatol 2012;22(1):42-5
   PubMed Web of Science ®Google Scholar
• Sertznig P, Reichrath J. Peroxisome proliferator-activated receptors (PPARs) in dermatology: challenge and promise. Dermatoendocrinol 2011;3(3):130-5
   PubMedGoogle Scholar
• Schuster M, Zouboulis CC, Ochsendorf F, et al. Peroxisome proliferator activated receptor activators protect sebocytes from apoptosis: a new treatment modality for acne? Br J Dermatol 2011;164(1):182-6
   PubMed Web of Science ®Google Scholar
• Michalik L, Wahli W. Peroxisome proliferator-activated receptors (PPARs) in skin health, repair and disease. Biochim Biophys Acta 2007;1771(8):991-8
   PubMed Web of Science ®Google Scholar
• Westergaard M, Henningsen J, Johansen C, et al. Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol 2003;121(5):1104-17
   PubMed Web of Science ®Google Scholar
• Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris: Identifier NCT00098358. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Kurzen H, Berger J, Jäger C, et al. Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skin. J Invest Dermatol 2004;123(5):937-49
   PubMed Web of Science ®Google Scholar
• Kurzen H, Schallreuter KU. Novel aspects in cutaneous biology of acetylcholine synthesis and acetylcholine receptors. Exp Dermatol 2004;13(suppl 4):27-30
   PubMedGoogle Scholar
• Li ZJ, Park SB, Sohn KC, et al. Regulation of lipid production by acetylcholine signalling in human sebaceous glands. J Dermatol Sci 2013;72(2):116-22
   PubMed Web of Science ®Google Scholar
• Baskaran P, Lehmann TE, Topchiy E, et al. Effects of enzymatically inactive recombinant botulinum neurotoxin type a at the mouse neuromuscular junctions. Toxicon 2013;72:71-80
   PubMed Web of Science ®Google Scholar
• Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol 2005;53(1):3-9
   PubMed Web of Science ®Google Scholar
• Shah AR. Use of intradermal botulinum toxin to reduce sebum production and facial pore size. J Drugs Dermatol 2008;7(9):847-50
   PubMedGoogle Scholar
• Rose AE, Goldberg DJ. Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin. Dermatol Surg 2013;39(3 Pt 1):443-8
   PubMed Web of Science ®Google Scholar
• Cartlidge M, Burton JL, Shuster S. The effect of prolonged topical application of an anticholinergic agent on the sebaceous glands. Br J Dermatol 1972;86(1):61-3
   PubMed Web of Science ®Google Scholar
• Clinical Trial To Evaluate ANT-1207 In Subjects With Acne: Identifier NCT01293552. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Rosignoli C, Nicolas JC, Jomard A, et al. Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo. Exp Dermatol 2003;12(4):480-9
   PubMed Web of Science ®Google Scholar
• Smythe CD, Greenall M, Kealy T. The activity of HMG-CoA reductase and acetyl-CoA carboxylase in human apocrine sweat glands, sebaceous glands, and hair follicles is regulated by phosphorylation and by exogenous cholesterol. J Invest Dermatol 1998;111(1):139-48
   PubMed Web of Science ®Google Scholar
• Strable MS, Ntambi JM. Genetic control of de novo lipogenesis: role in diet induced obesity. Crit Rev Biochem Mol Biol 2010;45(3):199-214
   PubMed Web of Science ®Google Scholar
• Thomson BioWorld. With $42M Series A, Dermira Amasses Dermatology Assets. 2011. Available from: http://www.pharmacychoice.com/News/article.cfm?Article_ID=797255 [Accesed 27 January 2014]
   Google Scholar
• A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel. Identifier NCT01936324. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne: Identifier: NCT00725439. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Baert B, De Spiegeleer B. Local skin pharmacokinetics of talarozole, a new retinoic acid-metabolism blocking agent. Skin Pharmacol Physiol 2011;24(3):151-9
   PubMed Web of Science ®Google Scholar
• Geria AN, Scheinfeld NS. Talarozole, a selective inhibitor of P450-mediated all-trans retinoin acid for the treatment of psoriasis and acne. Curr Opin Inventig Drugs 2008;9(11):1228-37
   PubMed Web of Science ®Google Scholar
• Stoppie P, Borgers M, Borghgraef P, et al. R115866 inhibits all-transretinoic acid metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther 2000;293(1):304-12
   PubMed Web of Science ®Google Scholar
• Van Wauwe JP, Van Nyen G, Coene MC, et al. Liarozole, an inhibitor of retinoic acid metabolism, exerts retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 1992;261(2):773-9
   PubMed Web of Science ®Google Scholar
• Pavez Loir E, Coold M, Borgers M, et al. Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis. Br J Dermatol 2009;160(1):26-36
   PubMed Web of Science ®Google Scholar
• Fritzsche B, Schuchardt JP, Schmidt A, et al. CYP26A1-specific antagonist influence on embryonic implantation, gene expression and endogenous retinoid concentration in rats. Reprod Toxicol 2010;30(3):446-51
   PubMed Web of Science ®Google Scholar
• Cuervo R, Chimal-Monroy J. Chemical activation of RARβ induces post-embryonically bilateral limb duplication during Xenopus limb regeneration. Sci Rep 2013;3:1886
   Google Scholar
• Webster GF. Acne vulgaris. BMJ 2002;325(7362):475-9
   PubMed Web of Science ®Google Scholar
• Selway JL, Kurczab T, Kealey T, et al. Toll-like receptor 2 activation and comedogenesis: implications for the pathogenesis of acne. BMC Dermatol 2013;13:10
   PubMedGoogle Scholar
• Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996;106(1):176-82
   PubMed Web of Science ®Google Scholar
• Ingham E, Eady EA, Goodwin CE, et al. Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992;98(6):895-901
   PubMed Web of Science ®Google Scholar
• Jungeau S, Tenaud I, Knoi AC, et al. Induction of toll-like receptors by Propinoebacterium acnes. Br J Dermatol 2005;153(6):1105-13
   PubMed Web of Science ®Google Scholar
• Graham GM, Farrar MD, Cruse-Sawyer JE, et al. Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P. acnes GroEL. Br J Dermatol 2004;150:421-8
   PubMed Web of Science ®Google Scholar
• XBiotech, Inc. "Treatment of inflammatory skin disease and psychiatric conditions". United States Patent US 2013/0039921 A1. Available from: https://www.google.com/patents [ Last Accessed 27 January 2014]
   Google Scholar
• Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris: Identifier NCT01474798. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed January 18 2014]
   Google Scholar
• Mahmood ZA, Mahmood SBZ. Antibiotic natural products: opportunities and challenges. In: Méndez-Vilas A, editor. Microbial pathogens and strategies for combating them: science, technology and education. Formatex Research Center, Badajoz, Spain; 2013
   Google Scholar
• Wiesner J, Vilcinskas A. Antimicrobial peptides: the ancient arm of the human immune system. Virulence 2012;1(5):440-64
   Google Scholar
• Sader HS, Fedler KA, Rennie RP, et al. Omiganan pentahydrochloride (MBI 226), a topical 12-amino-acid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother 2004;48(8):3112-18
   PubMed Web of Science ®Google Scholar
• Faccone D, Veliz O, Corso A, et al. Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates. Eur J Med Chem 2011;71C:31-5
   Google Scholar
• Alfred RL, ShagaghI NM, Palombo EA, et al. Tryptophan-rich antimicrobial peptides: properties and applications. In: Méndez-Vilas A, editor. Microbial pathogens and strategies for combating them: science, technology and education. Formatex Research Center, Badajoz, Spain; 2013
   Google Scholar
• Anderegg TR, Fritsche TR, Jones RN. Quality Control Guidelines for MIC susceptibility testing of omiganan pentahydrochloride (MBI 226), a novel antimicrobial peptide. J Clin Microbiol 2004;42(3):1386
   PubMed Web of Science ®Google Scholar
• Melo MN, Dugourd D, Castanho MA. Omiganan pentahydrochloride in the front line of clinical applications of antimicrobial peptides. Recent Pat Antiinfect Drug Discov 2006;1(2):201-7
   PubMedGoogle Scholar
• Safety and Efficacy of MBI 226 2.5% and 5.0% Topical Acne Solutions in the Treatment of Acne: Identifier NCT00211523 Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Safety and Efficacy of MBI 226 1.25% and 2.5% Topical Acne Solutions in the Treatment of Acne: Identifier NCT00211497. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed18 January 2014]
   Google Scholar
• Chambial S, Dwivedi S, Shukla KK, et al. Vitamin C in disease prevention and cure: an overview. Indian J Clin Biochem 2013;28(4):314-28
   PubMedGoogle Scholar
• Klock J, Ikeno H, Ohmori K, et al. Sodium ascorbyl phosphate shows in vitro and in vivo efficacy in the prevention and treatment of acne vulgaris. Int J Cosmet Sci 2005;27(3):171-6
   PubMedGoogle Scholar
• Woolery-Lloyd H, Baumann L, Ikeno H. Sodium L-ascorbyl-2-phosphate 5% lotion for the treatment of acne vulgaris: a randomized, doubleblind,controlled trial. J Cosmet Dermatol 2010;9(1):22-7
   PubMedGoogle Scholar
• 5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris: Identifier NCT00714454. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Wittmann M, Helliwell PS. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases. Dermatol Ther (Heidelb) 2013;3(1):1-15
   PubMedGoogle Scholar
• Crilly A, Robertson SE, Reilly JH, et al. Phosphodiesterase 4 (PDE4) regulation of proinflammatory cytokine and chemokine release from rheumatoid synovial membrane. Ann Rheum Dis 2011;70(6):1130-7
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Menter A, et al. Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study. J Drugs Dermatol 2013;12(8):888-97
   PubMed Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012;64(10):3156-67
   PubMed Web of Science ®Google Scholar
• Open Label Pilot Study of Apremilast in Treatment of Rosacea: Identifier NCT01045551. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Apremilast in the Treatment of Moderate to Severe Acne. Identifier NCT01074502. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Owyang AM, Issafras H, Corbin J, et al. XOMA 052, a potent, high affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. MAbs 2011;3(1):49-60
   PubMed Web of Science ®Google Scholar
• Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly 2012;142:w13590
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Wanderer AA. Inflammasome and IL-1beta-Mediated Disorders. Curr Allergy Asthma Rep 2010;10(4):229-35
   PubMed Web of Science ®Google Scholar
• Sahdo B, Särndahl E, Elgh F, et al. Propionibacterium acnes activates caspase-1 in human neutrophils. APMIS 2013;121(7):652-63
   PubMed Web of Science ®Google Scholar
• Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun 1995;63(8):3158-65
   PubMed Web of Science ®Google Scholar
• Qin M, Pirouz A, Kim MH, et al. Propionibacterium acnes induces IL-1β secretion via the NLRP3 inflammasome in human monocytes. J Invest Dermatol 2014;134(2):381-8
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013;5(1):1-4
   PubMed Web of Science ®Google Scholar
• Avelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012;35(8):1654-62
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris. Identifier NCT01498874. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Lee WJ, Choi YH, Kim DW. Expression of Inflammatory biomarkers from cultured sebocytes was influences by treatment with vitamin D. Indian J Dermatol 2013;58(4):327
   PubMedGoogle Scholar
• Isard O, Lévêque M, Knol AC, et al. Anti-inflammatory properties of a new undecyl-rhamnoside (APRC11) against P. acnes. Arch Dermatol Res 2011;303(10):707-13
   PubMed Web of Science ®Google Scholar
• Kramer C, Seltmann H, Seifert M, et al. Characterization of the vitamin D endocrine system in human sebocytes in vitro. J Steroid Biochem Mol Biol 2009;113(1-2):9-16
   PubMed Web of Science ®Google Scholar
• Kim BJ, Rho YK, Lee HI, et al. The effect of calcipotriol on the expression of human beta defensin-2 and LL-37 in cultured human keratinocytes. Clin Dev Immunol 2009;2009:645898
   PubMedGoogle Scholar
• Weber G, Heilborn JD, Chamorro-Jimenez CI, et al. Vitamin D induces the antimicrobial protein hCAP18 in human skin. J Invest Dermatol 2005;124(5):1080-2
   PubMed Web of Science ®Google Scholar
• Hayashi N, Watanabe H, Yasukawa H, et al. Comedolytic effect of topically applied active vitamin D3 analogue on pseudocomedones in the rhino mouse. Br J Dermatol 2006;155(5):895-901
   PubMed Web of Science ®Google Scholar
• Nieves NJ, Ahrens JM, Plum LA, et al. Identification of a unique subset of 2-methylene-19-nor analogs of vitamin D with comedolytic activity in the rhino mouse. J Invest Dermatol 2010;130(10):2359-67
   PubMed Web of Science ®Google Scholar
• Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy: Identifier NCT01694433. Clinical Trials: A service of the U.S National Institutes of Health. Available from: www.clinicaltrials.gov [Accessed 18 January 2014]
   Google Scholar
• Zeichner JA. Optimizing topical combination therapy for the treatment of acne vulgaris. J Drugs Dermatol 2012;11(3):313-17
   PubMed Web of Science ®Google Scholar
• Zaraa I, Belghith I, Ben Alaya N, et al. Severity of acne and its impact on quality of life. Skinmed 2013;11(3):148-53
   PubMedGoogle Scholar
• Alexis AF. Clinical considerations on the use of concomitant therapy in the treatment of acne. J Dermatolog Treat 2008;19(4):199-209
   PubMed Web of Science ®Google Scholar
• Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1%. J Eur Acad Dermatol Venereol 2007;21(6):747-53
   PubMed Web of Science ®Google Scholar
• Nelson AM, Gilliland KL, Cong Z, et al. 13-cis Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol 2006;126(10):2178-89
   PubMed Web of Science ®Google Scholar
• Knor T. Effect of topical retinoid therapy on seborrhea using iontophoresis. Med Arh 2003;57(5-6):295-8
   PubMedGoogle Scholar
• Katsambas A, Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther 2008;21(2):86-95
   PubMed Web of Science ®Google Scholar
• Kagayama K, Morimoto T, Nagata S, et al. Synthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors. Bioorg Med Chem 2009;17(19):6959-70
   PubMed Web of Science ®Google Scholar
• Zaenglein AL. Topical retinoids in the treatment of acne vulgaris. Semin Cutan Med Surg 2008;27:177-82
   PubMed Web of Science ®Google Scholar